BR112013018782A2 - compostos e seus efeitos no comportamento alimentar - Google Patents
compostos e seus efeitos no comportamento alimentarInfo
- Publication number
- BR112013018782A2 BR112013018782A2 BR112013018782A BR112013018782A BR112013018782A2 BR 112013018782 A2 BR112013018782 A2 BR 112013018782A2 BR 112013018782 A BR112013018782 A BR 112013018782A BR 112013018782 A BR112013018782 A BR 112013018782A BR 112013018782 A2 BR112013018782 A2 BR 112013018782A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- effects
- reduction
- eating behavior
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Abstract
resumo patente de invenção: "compostos e seus efeitos no comportamento alimentar". a presente invenção refere-se aos análogos de peptídeos de pyy, as composições compreendendo os referidos análogos e os métodos para o uso dos referidos análogos para o tratamento e a prevenção de desordens metabólicas, por exemplo, desordens do metabolismo energético, tais como diabetes e obesidade, e para a redução no apetite, redução na ingestão de alimentos ou redução de ingestão de calorias em um indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1101459.4A GB201101459D0 (en) | 2011-01-27 | 2011-01-27 | Novel compounds and thier effects on fedding behaviour |
PCT/GB2012/000086 WO2012101413A1 (en) | 2011-01-27 | 2012-01-27 | Novel compounds and their effects on feeding behaviour |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013018782A2 true BR112013018782A2 (pt) | 2016-11-22 |
Family
ID=43824713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013018782A BR112013018782A2 (pt) | 2011-01-27 | 2012-01-27 | compostos e seus efeitos no comportamento alimentar |
Country Status (13)
Country | Link |
---|---|
US (1) | US8901073B2 (pt) |
EP (1) | EP2668203A1 (pt) |
JP (1) | JP2014505069A (pt) |
KR (1) | KR20140007366A (pt) |
CN (1) | CN103459416A (pt) |
AU (1) | AU2012210308A1 (pt) |
BR (1) | BR112013018782A2 (pt) |
CA (1) | CA2825611A1 (pt) |
GB (1) | GB201101459D0 (pt) |
IL (1) | IL227386A0 (pt) |
RU (1) | RU2013139651A (pt) |
WO (1) | WO2012101413A1 (pt) |
ZA (1) | ZA201305493B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013014942B1 (pt) | 2010-12-16 | 2020-01-28 | Novo Nordisk As | composições sólidas para administração, e seus usos |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Glp-1 펩티드의 조성물 및 그것의 제조 |
AU2014261111B2 (en) * | 2013-05-02 | 2017-03-16 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
WO2015071356A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
MX369818B (es) | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
CN103834643A (zh) * | 2014-02-24 | 2014-06-04 | 华中农业大学 | 猪采食量调控酪酪肽基因pyy3’utr的遗传标记及其应用 |
WO2015177572A1 (en) | 2014-05-23 | 2015-11-26 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
WO2015177573A1 (en) * | 2014-05-23 | 2015-11-26 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
AU2016275735B2 (en) | 2015-06-12 | 2020-02-06 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
GB201720188D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Analogues of PYY |
PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
GB201908426D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
CN115362165A (zh) * | 2020-03-11 | 2022-11-18 | 安尼根有限公司 | 包含新型化合物的用于抗糖尿病和抗肥胖的组合物 |
IL297368A (en) | 2020-04-17 | 2022-12-01 | I2O Therapeutics Inc | Long-acting peptide tyrosine kinase (pyy) analogs and methods of use |
KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5571695A (en) | 1991-11-06 | 1996-11-05 | Garvan Institute Of Medical Research | Human neuropeptide Y-Y1 receptor |
WO1995005848A1 (en) | 1993-08-24 | 1995-03-02 | Novo Nordisk A/S | Protracted glp-1 |
US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US5962270A (en) | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
US6355478B1 (en) | 1996-06-17 | 2002-03-12 | Eli Lilly And Company | Rhesus monkey neuropeptide Y Y2 receptor |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
US6420352B1 (en) | 2000-07-19 | 2002-07-16 | W. Roy Knowles | Hair loss prevention |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
EP2050460A1 (en) | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
JP4733922B2 (ja) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | 摂食行動の修正 |
US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
JP5638177B2 (ja) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
WO2005077072A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP1807099A2 (en) | 2004-03-17 | 2007-07-18 | 7TM Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
EP2057996A3 (en) | 2004-03-17 | 2009-11-04 | 7TM Pharma A/S | Y4 selective receptor agonists for therapeutic intervention |
BRPI0508861A (pt) | 2004-03-17 | 2007-08-28 | 7Tm Pharmas As | agonistas do receptor y2/y4 seletivo para intervenções terapêuticas |
KR101272402B1 (ko) | 2004-12-13 | 2013-06-10 | 아스트라제네카 파마수티컬스 엘피 | 췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법 |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2614619A1 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2506273C2 (ru) | 2007-07-09 | 2014-02-10 | Импиэриэл Инноувейшнс Лимитид | Аналог панкреатического полипептида человека (варианты), фармацевтическая композиция на его основе, способ лечения ожирения или диабета, способ снижения аппетита, уменьшения поглощения пищи или снижения потребления калорий и способ косметического снижения массы посредством указанного аналога |
GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
-
2011
- 2011-01-27 GB GBGB1101459.4A patent/GB201101459D0/en not_active Ceased
-
2012
- 2012-01-27 JP JP2013550944A patent/JP2014505069A/ja active Pending
- 2012-01-27 WO PCT/GB2012/000086 patent/WO2012101413A1/en active Application Filing
- 2012-01-27 US US13/982,125 patent/US8901073B2/en not_active Expired - Fee Related
- 2012-01-27 EP EP12701542.8A patent/EP2668203A1/en not_active Withdrawn
- 2012-01-27 CA CA2825611A patent/CA2825611A1/en not_active Abandoned
- 2012-01-27 AU AU2012210308A patent/AU2012210308A1/en not_active Abandoned
- 2012-01-27 RU RU2013139651/10A patent/RU2013139651A/ru not_active Application Discontinuation
- 2012-01-27 BR BR112013018782A patent/BR112013018782A2/pt not_active IP Right Cessation
- 2012-01-27 KR KR1020137020251A patent/KR20140007366A/ko not_active Application Discontinuation
- 2012-01-27 CN CN2012800150898A patent/CN103459416A/zh active Pending
-
2013
- 2013-07-09 IL IL227386A patent/IL227386A0/en unknown
- 2013-07-19 ZA ZA2013/05493A patent/ZA201305493B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2668203A1 (en) | 2013-12-04 |
GB201101459D0 (en) | 2011-03-16 |
IL227386A0 (en) | 2013-09-30 |
CN103459416A (zh) | 2013-12-18 |
AU2012210308A1 (en) | 2013-08-01 |
WO2012101413A1 (en) | 2012-08-02 |
RU2013139651A (ru) | 2015-03-10 |
CA2825611A1 (en) | 2012-08-02 |
KR20140007366A (ko) | 2014-01-17 |
ZA201305493B (en) | 2016-07-27 |
US20130303443A1 (en) | 2013-11-14 |
US8901073B2 (en) | 2014-12-02 |
JP2014505069A (ja) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013018782A2 (pt) | compostos e seus efeitos no comportamento alimentar | |
BR112012018703A2 (pt) | compostos e seus efeitos sobre o comportamento alimentar | |
BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
BR112014004890A8 (pt) | Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria | |
BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
ECSP13012379A (es) | Pirimidinas y triazinas condensadas y su uso | |
BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
BR112012004696B8 (pt) | composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação | |
BR112016008540A2 (pt) | análogos de glucagon | |
EA200870365A1 (ru) | Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ | |
BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
BR112014007532A2 (pt) | variantes do fator de crescimento de fibroblastos 21 | |
BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
IN2014KN02830A (pt) | ||
BR112013027479A2 (pt) | "usos de um composto ou de um oligonucleotídeo modificado dirigidos a apociii, e medicamento compreendendo o referido composto" | |
CL2013002210A1 (es) | Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano. | |
MX344925B (es) | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. | |
MX2020003112A (es) | Composiciones de biguanida y metodos para tratar trastornos metabolicos. | |
BR112014016810A8 (pt) | composições e métodos para tratamento de distúrbios metabólicos | |
ECSP088849A (es) | Pirrolidinonas sustituidas de pieridinil como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
BRPI0908541B8 (pt) | uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas | |
BR112014003640A8 (pt) | métodos para perda de peso e composições cetogênicas | |
MX342257B (es) | Derivados y análogos de oxaspiro [2.5] octano. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |